Openbookopenbook
Equity
NIOX
+0.0 · +0.00%
GBX · LSE

NIOX Group PLC(NIOX) Stock Analysis | Healthcare

GBX --+0.00%
Reward58Moderate
Risk22Low
75%Data
2.4% dividend yield · Revenue growing 20% YoY
Defensive Anchor
Market Cap:286.19M
ⓘ
Reward Rating
58
Moderate
Reward Assessment
75% data coverage
Top 50% of stocksView factors
ⓘ
Risk Rating
22
Low
Risk Assessment
2 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on NIOX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for NIOX, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: 81p.

What is NIOX Group PLC?

NIOX Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis, monitoring, and management of asthma and COPD worldwide.

NIOX · Verdict

Solid reward · low risk

NIOX stands out on profitability and balance sheet, but watch the valuation signal.

Based on 88% data coverage

NIOX · Verdict

What’s working & what to watch

Strengths 4

  • Profitability92/100

    14% net margin · 11% ROE

  • Balance sheet92/100

    Interest covered 53.5×

  • Cash flow87/100

    32% free-cash-flow margin

  • Volatility75/100

    Above average

Watchouts 1

  • Valuation37/100

    P/E 57.5× · PEG 4.42

Model-based scoring. For information only — not financial advice.

What is NIOX Group PLC?

NIOX Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis, monitoring, and management of asthma and COPD worldwide. The company offers NIOX VERO, a non-invasive and point-of-care system that comprises a small portable device, sensors, individual disposable mouthpieces, and breathing handles for the measurement of fractional exhaled nitric oxide (FeNO) level in patients. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 286.19M, and a P/E ratio of 34.0x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (58)

The scoring profile indicates moderate reward potential, with profitability and growth as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Medical Devices names that are close enough in size to make side-by-side comparison useful.

MXCTMicro Cap / 162M market cap
MaxCyte Inc
Compare
EKFMicro Cap / 109M market cap
EKF Diagnostics Holdings Plc
Compare
AOTIMicro Cap / 106M market cap
AOTI Inc
Compare
Company Information
SectorHealthcare
IndustryMedical Devices
Market Cap286.19M
P/E Ratio34
Dividend Yield2.35%
Beta-0.095
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.